MedTrace Logo

Study to Evaluate the Effect of SLV320 in Addition to Chronic Furosemide Treatment on Renal Function in Subjects With Congestive Heart Failure and Impaired Renal Function

NCT00568009 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 300

Last updated 2008-04-22

No results posted yet for this study

Summary

This is a randomized, double-blind, placebo-controlled, multi-center, sequential cohort study in subjects with congestive heart failure (CHF) and impaired renal function who are on stable furosemide treatment (³ 40 mg daily). A total of 50 subjects will be randomized to each increasing dose level of SLV320 or placebo in a sequential fashion.

Conditions

  • Congestive Heart Failure

Interventions

DRUG

SLV320

1, 2.5, 5, 10 and 20 mg twice daily and placebo group. Duration of treatment 84 days

Sponsors & Collaborators

  • Quintiles, Inc.

    collaborator INDUSTRY

  • Solvay Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Global Clinical Director Solvay · Solvay Pharmaceuticals

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2007-10-31
Primary Completion
2008-11-30
Completion
2008-11-30

Countries

  • United States
  • Argentina
  • Belgium
  • Czechia
  • Germany
  • Poland
  • Russia
  • Serbia and Montenegro
  • South Africa
  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00568009 on ClinicalTrials.gov